English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The human leukocyte antigen-C ∗ 06 (HLA-C ∗ 06, formerly HLA-Cw6) is the main genetic biomarker in psoriatic disease. It has been related to several phenotypic traits in psoriatic disease, but its role in relation to cardiometabolic comorbidities is unknown at present. Here, we analyze the potential connections between this biomarker and the cardiometabolic profile of these patients. We carried out a cross-sectional observational study including 400 patients recruited at a single university hospital. Clinical and classical cardiometabolic factors were compared between HLA-C ∗ 06-positive and HLA-C ∗ 06-negative individuals (OR with 95% CI). Multivariate regression analyses were carried out to check for disease traits associated with different cardiometabolic risk factors. The study population included 215 men (53.8%) and 185 women (46.2%), mean age of  46 ± 15   years , and an average disease evolution of  17 ± 12.6   years . Ninety-three (23.3%) patients met CASPAR criteria for psoriatic arthritis. HLA-C ∗ 06 carriers ( n : 160, 40%) showed an earlier age at disease onset, psoriasis family history, and more severe skin disease (type I disease). After correcting for age, sex, and disease duration, they also showed less hypertension (13.8% vs. 24.2%, OR 0.7 (95% CI: 0.42-0.78),  p = 0.025 ), lower waist circumference ( 94.4 ± 13.7 vs.  98.3 ± 13.8   cm ), and lower BMI ( 27 ± 4.4 vs.  28.1 ± 4.8 ,  p &lt; 0.05 ). We confirmed the well-known association between HLA-C ∗ 06 and type I psoriatic disease. As a novel finding, patients carrying HLA-C ∗ 06 showed a better cardiometabolic profile. In any case, these findings need further confirmation.

biomed research international

Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C<math xmlns="http://www.w3.org/1998/Math/MathML" id="M1"> <mo>∗</mo> </math>06 Status

Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C ∗ 06 Status

Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C $*$ 06 Status